EMA Considers Cardiovascular Indication & Extra Market Protection For Wegovy

 
• By Neena Brizmohun

Novo Nordisk is seeking EU marketing approval to use its blockbuster obesity drug for reducing the risk of heart attack and stroke and it wants the European Medicines Agency to consider its request for an extra year of market protection.

Wegovy has been shown to reduce the risk of major adverse cardiovascular events • Source: Shutterstock

More from Europe

More from Geography